留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

乳腺癌靶向治疗的新策略

黄景彬 钟延强

黄景彬, 钟延强. 乳腺癌靶向治疗的新策略[J]. 药学实践与服务, 2011, 29(5): 324-327.
引用本文: 黄景彬, 钟延强. 乳腺癌靶向治疗的新策略[J]. 药学实践与服务, 2011, 29(5): 324-327.
HUANG Jing-bin, ZHONG Yan-qiang. New treatment strategies for targeted therapy of breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 324-327.
Citation: HUANG Jing-bin, ZHONG Yan-qiang. New treatment strategies for targeted therapy of breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 324-327.

乳腺癌靶向治疗的新策略

New treatment strategies for targeted therapy of breast cancer

  • 摘要: 目前,乳腺癌的常规治疗手段如化疗、放疗等存在严重的全身副作用,为此,开展乳腺癌的靶向治疗研究具有重大意义。本文综述了乳腺癌靶向治疗的3个研究领域:抗体介导的靶向、微载体介导的靶向、乳腺癌干细胞靶向,并阐述这些治疗策略的基本研究思路,分析这些新的治疗策略面临的一些问题,从而提出解决这些问题的相关见解。
  • [1] Normanno N, Morabito A, De Luca A, et al. Target-based therapies in breast cancer: current status and future perspectives[J]. Endocr Relat Cancer, 2009, 16 (3): 675.
    [2] Aesoy R, Sanchez BC, Norum JH, et al. An autocrine VEGF/VEGFR-2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells[J]. Mol Cancer Res, 2008, 6 (10): 1630.
    [3] Le XF, Mao W, Lu C, et al. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2[J]. Cell Cycle, 2008, 7 (23): 3747.
    [4] Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances[J]. Oncologist, 2005, 10 (6): 382.
    [5] Cesare G, PaoloM, Antonio R, et al. The role of bevacizumab in the treatment of non-small cell lung cancer: current Indications and future developments[J]. The Oncologist, 2007, 12 (10) : 1183.
    [6] Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for matastatic breast cancer[J]. N Engl J Med, 2007, 357 (26): 2666.
    [7] Park JW,Neve RM, Szollosi J,et al. Unraveling the biologic and clinical comp lexities of HER2[J]. Clin Breast Cancer, 2008, 8 (5) : 392.
    [8] Freudenberg JA,Wang Q, Katsumata M, et al. The role of HER2 in early breast cancermetastasis and the origins of resistance to HER2-targeted therapies[J]. Exp Mol Pathol, 2009, 87 (1) : 1.
    [9] SpectorNL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor-2 positive breast cancer[J]. J Clin Oncol, 2009, 27 (34) : 5838.
    [10] Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies[J]. Lancet Oncol, 2009, 10 (12) : 1179.
    [11] Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the HSP90 inhibitor tanesp imycin (Tan) + trastuzumab (T) in patients ( pts) with HER2-positive metastatic breast cancer (MBC) [J]. J ClinOncol, 2008, 26 (5) : 1027.
    [12] Mulik RS, Mnkknen J, Juvonen RO, et al. Transferrin mediated solid lipid nanoparticles containing curcumin: Enhanced in vitro anticancer activity by induction of apoptosis[J]. Int J Pharm, 2010, 398 (1-2): 190.
    [13] Zheng Y, Yu B, Weecharangsan W,et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells[J]. Int J Pharm, 2010, 390 (2): 234.
    [14] Acharya S,Dilnawaz F, Sahoo SK, et al. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy[J]. Biomaterials, 2009, 30 (29): 5737.
    [15] Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature[J]. Biomaterials, 2010, 31 (8): 2278.
    [16] Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138 (4): 645.
    [17] Riccioni R, Dupuis ML, Bernabei M, et al. The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor[J]. Blood Cells Mol Dis, 2010, 45 (1): 86.
    [18] Fuchs D, Heinold A, Opelz G, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells[J]. Biochem Biophys Res Commun, 2009 , 390 (3): 743.
    [19] Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancercells to chemotherapy[J]. J Natl Cancer Inst, 2008, 100 (9): 672.
    [20] Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses[J]. Breast Cancer Res Treat, 2008, 112: 533.
    [21] Liu Y, Lu WL, Guo J, et al. A potential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes[J] J Control Release, 2008, 129 (1): 18.
    [22] Zhou J, Zhang H, Gu P, et al. NF-kB pathway inhibitors preferentially inhibit breast cancer stem-like cells[J]. Breast Cancer Res Treat, 2008, 111 (3): 419.
    [23] Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission[J]. Cancer Res, 2009, 69 (19): 7507.
    [24] Anisimov VN, Egormin PA, Piskunova TS, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo[J]. Cell Cycle, 2010, 9 (1): 188.
    [25] Liu B, Fan Z, Edgerton SM, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells[J]. Cell Cycle, 2009, 8(13): 2031.
    [26] Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100 (7): 3983.
    [27] Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics[J]. Breast Cancer Res, 2008, 10 (1): R10.
    [28] Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers[J]. PLoS One, 2009, 4 (12): e8377.
    [29] Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1 (5): 555.
    [30] Pece S, Tosoni D, Confalonieri S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content[J]. Cell, 2010, 40 (1): 62.
  • [1] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [2] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [3] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [4] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [5] 孙丹倪, 黄勇, 张嘉宝, 王培.  代谢相关脂肪性肝病的无创诊断与药物治疗的新观点和未来展望 . 药学实践与服务, 2024, 42(10): 411-418. doi: 10.12206/j.issn.2097-2024.202403049
    [6] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [7] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [8] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [9] 陈莹, 许子华, 胡北, 崔亚玲, 高欢, 吴琼.  通便灵胶囊治疗便秘的药效与机制研究 . 药学实践与服务, 2024, 42(): 1-7. doi: 10.12206/j.issn.2097-2024.202404008
    [10] 宋泽成, 陈林林, 鲁仁义, 刘梦肖, 王彦.  脓毒症治疗的研究进展 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202405059
    [11] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
    [12] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [13] 张莲卿, 骆岩, 杨提, 姚佳晨, 李文艳.  基于FAERS数据库的艾塞那肽微球不良事件信号挖掘与研究 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202403057
    [14] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [15] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
  • 加载中
计量
  • 文章访问数:  3037
  • HTML全文浏览量:  331
  • PDF下载量:  548
  • 被引次数: 0
出版历程
  • 收稿日期:  2010-12-30
  • 修回日期:  2011-03-17

乳腺癌靶向治疗的新策略

摘要: 目前,乳腺癌的常规治疗手段如化疗、放疗等存在严重的全身副作用,为此,开展乳腺癌的靶向治疗研究具有重大意义。本文综述了乳腺癌靶向治疗的3个研究领域:抗体介导的靶向、微载体介导的靶向、乳腺癌干细胞靶向,并阐述这些治疗策略的基本研究思路,分析这些新的治疗策略面临的一些问题,从而提出解决这些问题的相关见解。

English Abstract

黄景彬, 钟延强. 乳腺癌靶向治疗的新策略[J]. 药学实践与服务, 2011, 29(5): 324-327.
引用本文: 黄景彬, 钟延强. 乳腺癌靶向治疗的新策略[J]. 药学实践与服务, 2011, 29(5): 324-327.
HUANG Jing-bin, ZHONG Yan-qiang. New treatment strategies for targeted therapy of breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 324-327.
Citation: HUANG Jing-bin, ZHONG Yan-qiang. New treatment strategies for targeted therapy of breast cancer[J]. Journal of Pharmaceutical Practice and Service, 2011, 29(5): 324-327.
参考文献 (30)

目录

    /

    返回文章
    返回